Day 1: Sunday, December 7, 2025
Hepatitis elimination is not achievable without a SEARCH
Miriam Levy - Liverpool Hospital and UNSW, Australia
Special Lecture: Checkpoint therapy for hepatocellular carcinoma – 2025 and beyond
George Lau - Humanity and Health Medical Center, Hong Kong, China
Day 2: Monday, December 8, 2025
William H. Prusoff HEP-DART Lifetime Achievement Award & Lecture
William H. Prusoff HEP-DART Lifetime Achievement Award lecture: My journey towards treating viral hepatitis
Marion Peters, University of San Francisco, USA
Updates in guidance and approach to HBV and HCV in pregnant people - critical population for our path to HBV/HCV Elimination
Tatyana Kushner - Weill Cornell Medicine, USA
SESSION 3: Hepatitis B basic science, immunology, and therapeutics (Hepatitis B Foundation sponsored session)
Plenary Lecture: Basic research for hepatitis B infections
Barbara Testoni - Lyon University, France
Merging WHO, EASL, AASLD and the China HBV Guidelines
Markus Cornberg - Medical School Hannover, Germany
The future of IFN-based therapies for HBV cure
Lefteris Michailidis - Emory University, USA
Oral Abstract Session II
Discovery of HS-83128: An orally bioavailable, liver-targeted dihydroquinolizinone with in vivo efficacy against HAV and HBV
Yanming Du - Baruch S. Blumberg Institute, USA
Efficacy of E-CFCP, a novel long-acting anti-HBV nucleoside analog, on chronic hepatitis B in humanized liver chimeric mice
Hiroaki Mitsuya - Japan Institute for Health Security, Tokyo, Japan - National Institutes of Health, USA
ASO therapeutics: a breakthrough to transform CHB treatment for functional cure
Guofeng Cheng - Ausper Bio, USA
HBV reactivation associated with CAR-T therapy: recommendations for prompt and prolonged antiviral prophylaxis
Adrian Di Bisceglie - Saint Louis University, USA
Day 3: Tuesday, December 9, 2025
SESSION 4: New advances in HBV Cure
Plenary Lecture: HBV cure - what are the risks and rewards
Ed Gane - University of Aukland, New Zealand
Novel antivirals for HBV functional cure
Mark Sulkowski - Johns Hopkins University, USA
In vivo efficacy of a CAM from the magnitude of the first phase decline in HBV RNA
Alan Perelson - Los Alamos National Laboratory, USA
HBV vaccines in people living with HIV and current HCV vaccine efforts
Andrea Cox - Johns Hopkins University, USA
Using CHIM (Controlled Human Infection Model) to accelerate HCV vaccine development
Jordan Feld - UNH, Canada
SESSION 6: Industry session: Getting closer to HBV and MASH curative modalities
Development and approval of resmetirom, a thyroid hormone receptor beta agonist for the treatment of MASH with liver fibrosis
Rebecca Taub - Madrigal Pharmaceuticals, USA
Profiling T-cell responses and HBV neutralization activity in a large cohort of participants with chronic hepatitis B who achieved functional cure
Jenny Svarovkaia - Gilead, USA
Advances in chronic HBV treatment with bepirovirsen
Charlene Prazma - GSK, USA
PBGENE-HBV, a first-in-class gene editing therapy for chronic hepatitis B, demonstrates safety and antiviral activity across three cohorts
Man-Fung Yuen, Principal Investigator, Hong Kong - Precision Biosciences
Addressing an unmet need in chronic hepatitis Delta
Todd Correll - Vir Biotechnologies, USA
Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks
Larry Blatt - Aligos, USA
Day 4: Wednesday, December 10, 2025
SESSION 7: Advancements in MASH and MASLD
Plenary talk: MASLD and cardiovascular disease
Laurence Sperling - Emory University, USA
Reasonably likely surrogate endpoint for MASH - road to validation
Veronica Miller - University of California, Berkeley, USA
Special Lecture: GLP-1s and combination— the impact of these drugs cannot be understated and will influence future drug development for MASLD/MASH
Arun Sanyal - Virginia Commonwealth University, USA
SESSION 8: Advances in Hepatitis D therapeutics
Plenary Lecture: The HDV epidemic – is the problem bigger or smaller than we think and will this affect the treatment landscape?
Pietro Lampertico - University of Milan, Italy
Emerging therapies for hepatitis D and long-term outcomes of antiviral treatment in chronic viral hepatitis
Tarik Asselah - Hospital Beaujon, France
Oral Abstract Session III
The effectiveness of bulevirtide monotherapy is similar in chronic hepatitis delta patients with and without cirrhosis results from the prospective multicenter D-Shield study
Maria Paola Anolli - University of Milan, Italy
SESSION 9: Advances in Hepatocellular Cancer Treatment
Plenary Lecture: HCC: the path to molecular targeting: HCC is a "drugable" cancer
Richard Finn - UCLA, USA
Oral Abstract Session IV (15:30-16:30)
From viral hepatitis to metabolic dysfunction: nationwide inpatient outcomes of HCV- and MASLD-related hepatocellular carcinoma, 2020–2022
Muhammad Haris Latif - SSM St Mary’s Hospital, USA
Microbial biotherapeutic metabolite alleviates liver injury by restoring lipid metabolism and gut-liver axis homeostasis via PPARα
Satya Dandekar - University of California Davis, USA
The HDAg acidic cluster mimicking the host histones nucleosome acidic patch is crucial for viral replication
Massimo Levero - INSERM, France
Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
Xuan (Susan) Luong - Aligos Therapeutics, USA
Histotripsy, a novel non-invasive therapy for liver tumors: An outpatient medical management experience
Tarek Hassanein - Southern California Liver Centers, USA
BUSINESS DISCUSSION SESSION: (Non-CME)
Business of therapeutics for hepatitis and liver diseases
Geoff Meacham - Citi Bank, USA
Tavi Yehudai - Trails Edge Capital Partners, USA
Day 5: Thursday, December 11, 2025
SESSION 10: Alternative approaches for cure
Plenary Lecture: Gene editing and epigenetic modification for HBV cure
Fabien Zoulim - Lyon University, France
Strengths and weaknesses of the HBV ribonuclease H as a drug target
John Tavis - Washington University in St. Louis, USA
Curing HBV by safely modifying the immune system
Adam Gehring - UHN Toronto, Canada
Oral Abstract Session V (10:40-11:20)
ROR⍺ controls hepatocyte extracellular vesicle loading of the immunomodulatory lncRNA MALAT-1
Rabindra Tirouvanziam - Emory University, USA
Pregnancy outcomes in women with hepatitis C: a nationwide propensity-matched analysis
Yassine Kilani - Saint Louis University School of Medicine, USA
Final Session
2025 & Beyond: Sea of change and navigating turbulent times
Robert Gish - Antivirals & viral diseases
Adrian Di Bisceglie - MASH & liver diseases